HuiXin Bio Completes Tens of Millions RMB Pre-A Financing to Address Bottlenecks in Exosome Applications

VCBeat (WeChat ID: vcbeat) has learned that Shenzhen Huixin Lifetech Co., Ltd. (“Huixin Lifetech”) announced the completion of its Pre-A financing round, amounting to tens of millions of yuan. The round was led by Weidu Venture Capital, with participation from Lvhe Investment, and existing shareholder Kaifeng Venture Capital made a pro-rata-plus follow-on investment. The proceeds will be used for the in-depth development and mass production of exosome purification equipment and systems, as well as to advance clinical research and market launch of exosome-based diagnostic and therapeutic products.

Huixin Lifetech was founded by renowned scientists and industry experts in the field of exosomes,Committed to developing world-leading biotechnologies and products, advancing the application of exosomes in cancer diagnosis and cell therapy.Its core team boasts extensive experience in academic research, product development, and market expansion. Since its inception, Huixin Lifetech has collaborated with multiple research institutions by leveraging industry-leading technical talent. Combining this expertise with the team’s rich experience in medical device development, the company launched EXODUS®, the world’s first label-free automated purification system for exosome isolation and purification. The product has garnered widespread attention within the industry since its launch and has been recognized by numerous research institutions and third-party medical testing laboratories.

Compared with other traditional separation and purification methods, EXODUS® enables the acquisition of exosomes with higher purity, higher recovery rates, and greater integrity in a shorter time. Furthermore, leveraging its advanced exosome purification technology platform, Huixin Lifetech has also made significant progress in areas such as the development of diagnostic kits for urological tumors and the large-scale preparation of stem cell-derived exosomes.

Yang Yijie, General Manager of Huixin Lifetech, stated: We extend our gratitude to the investors in this funding round for their recognition and support of Huixin Lifetech. Over the past year, we have optimized, upgraded, and scaled up the production of our existing technologies, earning recognition from research users and experts in the exosome industry. Huixin Lifetech will continue to uphold technological innovation, promoting the application of exosomes in early cancer diagnosis, cell therapy, and regenerative medicine. We will persist in developing a series of products to address urgent market demands, providing advanced technical support for basic research and clinical applications of exosomes in China, and contributing to the creation of an accessible ecosystem for the prevention and treatment of major diseases driven by Chinese innovation, as well as to the upgrading of the healthcare industry.

The lead investor in this round, Weidu Ventures, statedExosomes have demonstrated significant potential in the treatment, diagnosis, and medical aesthetic repair of various complex diseases, including tumors and neurological disorders, offering broad application prospects. Huixin Lifetech is positioned to address bottlenecks in exosome applications; its developed exosome extraction equipment is poised to become a key tool for separation and purification in the upstream segment of the exosome industry chain, thereby accelerating progress in downstream applications. The core team members of Huixin Lifetech possess composite backgrounds and extensive experience in academic research, product development, and commercialization of exosomes. It is believed that, under the leadership of its founding team, the company will drive the development of the exosome industry in the medical and health sectors. Weidu Ventures will uphold its belief of “helping entrepreneurs cross from this shore to the other” and accompany the company throughout its growth journey.

Angel investor Kaifeng Venture Capital statedKaifeng Venture Capital has been deeply committed to the field of precision medicine. As exosome testing is a critical component of precision diagnosis and treatment, we continue to closely monitor its technological advancements and industrialization opportunities. Upon the publication of the innovative technology developed by Huixin Lifetech, our team was immediately drawn to its unique technical principles and significant commercial potential, leading us to swiftly complete an angel investment in the company. We are delighted to witness Huixin Lifetech’s rapid growth over the past year and have had the privilege of observing the numerous achievements of the EXODUS® technology in the field of exosome isolation and purification. We look forward to advancing further together with Huixin Lifetech in the exosome sector, supporting Huixin in becoming a leading enterprise in the industry.

Green River Investment, a co-investor in this round, stated:Exosomes, characterized by their broad-spectrum secretion, targeted delivery capabilities, and diverse cargo, hold immense research value and clinical application potential, thereby attracting significant scientific investment and capital attention. Research and clinical translation of exosomes have reached a peak, with a growing number of participating enterprises expanding in scale. Huixin Lifetech boasts a team with specialized expertise in exosome technology and extensive experience in the medical device sector, positioning it to help address key challenges in the domestic and global exosome industry, such as purification and enrichment, targeted delivery, and drug loading. Green River Investment firmly believes that “technology creates value, and growth enhances value.” As proactive investors, we are committed to accompanying Huixin Lifetech on its long-term journey of shared growth.